FMC Diablo West Antioch is a medicare approved dialysis facility center in Antioch, California and it has 15 dialysis stations. It is located in Contra Costa county at 2386 Buchanan Road, Antioch, CA, 94509. You can reach out to the office of FMC Diablo West Antioch at (925) 756-2490. This dialysis clinic is managed and/or owned by Fresenius Medical Care. FMC Diablo West Antioch has the following ownership type - Profit. It was first certified by medicare in June, 1998. The medicare id for this facility is 052831 and it accepts patients under medicare ESRD program.
| Name | FMC Diablo West Antioch |
|---|---|
| Location | 2386 Buchanan Road, Antioch, California |
| No. of Dialysis Stations | 15 |
| Medicare ID | 052831 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | Yes |
| 2386 Buchanan Road, Antioch, California, 94509 | |
| (925) 756-2490 | |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
| NPI Number | 1528213261 |
| Organization Name | Fresenius Medical Care-diablo West Antioch |
| Doing Business As | Fresenius Medical Care Diablo Nephrology Clinics Llc |
| Address | 2386 Buchanan Rd Antioch, California, 94509 |
| Phone Number | (925) 756-2490 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
| NPI Number | 1912019712 |
| Organization Name | Diablo Renal Services - Antioch |
| Doing Business As | Bio-medical Applications Of California, Inc. |
| Address | 2386 Buchanan Rd Antioch, California, 94509 |
| Phone Number | (925) 756-2490 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 70% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 11% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 19% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 69% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 18% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 13% | 14% |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 66% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 21% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 13% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 66% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 30% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 4% | 12% |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 76% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 24% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 63% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 31% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 6% | 12% |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
| Dialysis patients with Hemoglobin data | 62 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 5 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 81 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 754 |
| Percentage of adult patients getting regular hemodialysis at the center | 98 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at FMC Diablo West Antioch with elevated calcium levels.
| Patients with hypercalcemia | 93 |
| Hypercalcemia patient months | 878 |
| Patients with Serumphosphor | 91 |
| Patients with Serumphosphor less than 3.5 mg/dL | 6 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 41 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 19 |
| Patients with Serumphosphor greater than 7 mg/dL | 11 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 90 |
| Patient months included in arterial venous fistula and catheter summaries | 742 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 70 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 8 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 87 |
| Hospitalization Rate in facility | 188.2 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 307.4 |
| Hospitalization Rate: Lower Confidence Limit | 118.3 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
The rate of readmission show you whether patients who were being treated regularly at FMC Diablo West Antioch were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 27 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 39.3 |
| Readmission Rate: Lower Confidence Limit | 16.8 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at FMC Diablo West Antioch get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .69 (As Expected) |
| SIR: Upper Confidence Limit | 1.67 |
| SIR: Lower Confidence Limit | .22 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether FMC Diablo West Antioch's rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 78 |
| Transfusion Rate in facility | 30.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 78.8 |
| Transfusion Rate: Lower Confidence Limit | 13.4 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
The rate of mortality show you whether patients who were being treated regularly at FMC Diablo West Antioch lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 434 |
| Mortality Rate in facility | 21.4 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 28 |
| Mortality Rate: Lower Confidence Limit | 16 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago
FMC Diablo West Antioch Location: 2386 Buchanan Road, Antioch, California, 94509 Phone: (925) 756-2490 |
Antioch Dialysis Center Location: 3100 Delta Fair Blvd, Antioch, California, 94509 Phone: (925) 753-5000 |
Davita Lone Tree Ranch Dialysis Location: 4040 Lone Tree Way, Antioch, California, 94531 Phone: (925) 777-3356 |
News Archive
Takeda Pharmaceutical Company Limited ("Takeda") today announced that its wholly owned subsidiary, Takeda Global Research & Development Center, Inc. (U.S.), received on September 2 (U.S. TIME), a complete response letter from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for the fixed-dose combination (FDC) of alogliptin and ACTOS(R) (pioglitazone HCl).
A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer. The findings could lead to better tests for predicting whether a woman's breast cancer will spread and to new anti-cancer therapies.
It's difficult to practice skills on preterm babies who are in neonatal intensive care units (NICU). The complications associated with preterm babies can be varied and infrequent, making it hard for staff to develop their skills set.
The Collaborative Spine Research Foundation (Collaborative Spine) today announced it has completed the process of setting a research agenda for spine care. The agenda articulates the most critical clinical research issues that need to be addressed in order to deliver on the Foundation's commitment to advance the science and practice of the highest-quality spine care.
› Verified 8 days ago